Vitamins and Age-Related Macular Degeneration
What we know so far and where we are headed.
SHANTAN REDDY, MD, MPH & HOWARD
F. FINE, MD. MHSC
macular degeneration is the leading cause of severe, irreversible visual loss in
developed countries. It affects 4 to 10 million Americans between the ages of 45
and 75. The disease process is considered to begin as a non-neovascular form after
which some patients may develop a neovascular form. Though neovascular AMD may be
responsible for the majority of those with severe visual loss, 80% of AMD patients
are expected to have the non-neovascular form. No treatment to date has been found
to prevent the occurrence of AMD.
Table. AREDS Formulation
400 international units
The pathogenesis of this disease is believed to be multifactorial,
involving genetic factors, inflammatory factors, oxidative stress, and other factors.
The macula may be highly susceptible to oxidative stress since it has a high concentration
of polyunsaturated fatty acids and is continuously exposed to light and oxygen.1
There is strong evidence suggesting that lipofuscin is derived from oxidatively
damaged photoreceptors. It has also been shown that age-related oxidation occurred
more aggressively in groups assigned to no antioxidant supplementation as compared
to those who received supplementation.2
The retina's defenses to such processes include enzymes, such as selenium-dependent
glutathione (GSH) peroxidases and catalases, and antioxidant nutrients such as vitamins
E and C and carotenoids.1
With this understanding, it has been hypothesized that people with low levels of
these antioxidants may be more prone to oxidative damage in the retina, which may
ultimately lead to AMD. Taking this a step forward, consuming higher levels of these
antioxidants may protect an individual from developing AMD.
Prior to the Age-Related Eye Disease Study
(AREDS), many epidemiologic studies have provided some support to this hypothesis,
though the results were inconsistent. The National Health and Nutrition Examination
Survey (NHANES) found that the intake of fruits and vegetables rich in vitamin A
was lower in those subjects with AMD.3
The Pathologies Oculaires Liees a l'Age (POLA) Study demonstrated a relationship
between alpha-tocopherol and AMD, finding a weak protective association with late
Given the lack of definitive evidence for the beneficial effect of antioxidant supplementation
and the growing concern of widespread use of unproven, high-dose supplements, the
National Eye Institute performed a randomized, multi-centered, placebo controlled
clinical trial designed to evaluate the effect of high doses of zinc, vitamins C
and E, and beta-carotene on the incidence and progression of AMD.
Figure 1. Fundus photograph to illustrate drusen
size. (Excerpted with permission from AREDS report no.18) In the 8-o'clock meridian, about 1 disc diameter from the center
of the macula, there is a large druse, slightly larger than the minimum required
to meet the �125 μm (width
of an average large vein at the disc margin) definition. At 5:30, near the edge
of the photograph, there is an intermediate druse, defined as �63 μm
but <125 μm in diameter.
The first AREDS study enrolled 3640 subjects,
who had an average follow-up of 6.3 years, few of whom (2.4%) were lost to follow-up.
Subjects in the intervention group were assigned to vitamin doses that were 5 to
15 times the recommended dietary allowances (RDA) [C (500 mg) and E (400 IU), beta-carotene
(15 mg), zinc oxide (80 mg with 2 mg of copper)] (Table).5
The initial high dose of zinc at 80 mg was chosen in AREDS because of a reported
beneficial effect at this dose in a previous study.6
The participants were divided into 4 groups. One group received
the antioxidants alone, 1 received the antioxidants plus zinc, the other zinc alone,
and 1 group received placebo, serving as the control. Participants could be enrolled
with few to no drusen, and 1 eye had to have a visual acuity (VA) of 20/32 or better.
Patients were categorized into 4 groups. Category 1 was intended to evaluate the
effect of supplementation on cataract progression. Category 2 had multiple small
drusen, few intermediate drusen, or pigmentary changes. Category 3 had extensive
intermediate drusen or any amount of large drusen. And Category 4 had advanced AMD
in only 1 eye, which was defined as geographic atrophy involving the fovea, choroidal
neovascularization, or exudative detachments (Figures 1, 2). The study reported
that zinc alone, antioxidants alone, or the combination of the 2 modestly prevented
the progression to advanced AMD from Categories 3 and 4. Furthermore, they found
that the combination of antioxidants and zinc was more effective than either group
alone. Specifically, the vitamin formulation decreased the risk of advanced AMD
by 25% for participants with intermediate AMD. Participants who began the study
with early AMD were so unlikely to develop advanced AMD (1.3%) during the course
of their study that the beneficial effect on this group could not be evaluated.
Combination formulations also decreased the risk of moderate visual loss of 3 lines
or more at 5 years compared to baseline by about 19%. Those receiving either antioxidants
alone or zinc alone failed to achieve statistical significance.5
The AREDS group also examined the effects of treatment with AREDS
formulation on the progression of further vision loss in eyes with advanced AMD
and the effects on mortality.7
They found that persons assigned to the antioxidants alone had a reduced risk of
progression to VA loss of
3 lines. Those in the zinc group alone or the combination
group also enjoyed a protective effect. They reported that after a median follow-up
of 6.5 years, 11% of the
4753 AREDS participants had died. Mortality increased
with worsening macular pathology. Though a relationship between zinc and Alzheimer's
disease has been reported, AREDS found a decreased mortality (relative risk = 0.73)
associated with a dose of 80 mg and there were no cognitive deficiencies found in
participants. Furthermore, vitamin E was not found to increase the risk of mortality.
They concluded that the AREDS formulation is safe for patients with intermediate
AMD and those with advanced disease in 1 eye.
illustrated potential weakness in this study that should be considered when interpreting
First, the exclusion of Category 2 patients from many of the analyses is troubling
because it occurred after reviewing the data. Second, the trial was only marginally
powerful in demonstrating a beneficial effect of the vitamins, though it had a long
follow-up. Third, many of the results were reported as trends since they did not
meet statistical significance set a priori. Fourth, we cannot determine which or
if all of the antioxidants provided the protective effect.
Since the publications of AREDS results,
many studies have looked at the effects of supplementation and dietary intake on
early AMD. The Blue Mountain Eye Study in Australia used a questionnaire to assess
the intake of 11 micronutrients which included, among others, lutein, zeaxanthin,
vitamin A and C via diet, zinc via diet, and
The study found no significant associations or trends between dietary intake or
dietary intake combined with zinc and the incidence of early AMD, the 5-year incidence
of AMD, or the 5-year progression from category 1 or 2 to category 3 or 4. The Blue
Mountain Eye Study also reported on the association between vitamin and zinc supplementation
and the prevalence of AMD.10
They found no benefit for any type of supplement. The results of these
cannot be overlooked given their large sample sizes (2335 patients and 2873 patients,
respectively). The vitamin E, cataract, and age-related maculopathy trial (VECAT),
a double-masked randomized, placebo controlled trial, found no benefit of daily
vitamin E supplements in reducing the risk of early AMD or preventing the progression
2. Fundus photographs from participants in the AREDS illustrating eyes in AMD Categories
2 and 3.
with permission from AREDS report no. 8)(5)
A. Left eye in Category 2 shows nonextensive intermediate drusen,
mostly located superotemporal to the center of the macula. No druse is 125 μm
or greater in diameter, although some are 63 μm
or greater and their cumulative area is less than AREDS circle O-2 (about 0.2 disc
areas). B. One left eye in Category 3 depicts the lower limit of the category, having
1 large druse (�125 μm in
diameter) in the 8-o'clock position from the center of the macula, while another
left eye (C) shows many large drusen (totaling at least 1 disc area) scattered throughout
THE SOCIAL IMPACT
Bressler and associates more recently estimated
the potential public health impact of the findings of AREDS on reducing the number
persons developing advanced AMD over 5 years.12
They determined that more than 300 000 people with intermediate AMD would avoid
advanced AMD and any associated visual loss over 5 years if they were compliant
with the recommendations. However, Jampol found that only 42% of his patients were
on the correct dosage of supplementation in his office.13
A trial following AREDS found that only 45% of participants eligible for supplementation
were taking the AREDS type formulation (Frederick Ferris, MD, unpublished data 2003).
Though compliance may not be as high as reported in the AREDS
study (75%), many patients have become informed about the availability of antioxidant
products and the claims made for their benefit. Consequently, their use is becoming
more widespread. A survey was conducted to compare the ingredients of various products
with the current AREDS recommendations. The survey identified
22 eye nutrient
products. Although 75% of the products contained all the constituents present in
the AREDS formulation, only 2 contained the dosages recommend by the AREDS study.14
Then, in order to reap the entire benefits put forth by Bressler and associates,
ophthalmologists need not only stress compliance, but must also familiarize themselves
with the various products and educate their patients on which brands of supplements
they should take.
Like any intervention, the potential for
adverse outcomes cannot be overlooked. The AREDS reported an increased risk for
genitourinary hospitalization (urinary tract infections, prostatic hyperplasia,
and stress incontinence) in patients taking zinc; however, this was only a trend.5
Vitamin E may not be advisable for patients with bleeding problems or who are on
anticoagulation. There have been findings of an increased risk of intracerebral
and subarachnoid hemorrhage during treatment with carotene and alpha-tocopherol.15
Other evidence has shown that large amounts of vitamin A may lead to osteoporosis
and hip fractures.16
More importantly, in light of strong evidence showing that beta-carotene may be
harmful in smokers, most ophthalmologists now recommend high doses of vitamins E
and C and zinc without beta-carotene to smokers or ex-smokers. However, we still
cannot say with certainty that this combination without beta-carotene is as effective
as the combination given in AREDS.
3. Approximate 5-year rates of progression to advanced AMD.
EXCERPTED WITH PERMISSION
FROM AREDS REPORT NO.18(27)
This brings up another issue, which is the
beneficial effect of other carotenoids such as leutin and zeaxanthin, since ophthalmologists
are now reluctant to use beta-carotene. A case-control study in the Netherlands
found that the prevalence of AMD in patients with low-antioxidant intake and low-lutein
intake was twice that found in patients with high intake.17
Other epidemiologic studies showed that patients with low-dietary intake of leutin
and omega-3 fatty acids have an increased risk associated with AMD.18,19
The National Eye Institute is conducting
another study, AREDS II, to determine whether oral supplementation with leutin at
10 mg/d and zeaxanthin at 2 mg/d and/or omega-3 long-chain polyunsaturated fatty
acids (LCPUFA, docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA] at a total
of 1 g/d) will decrease the risk of progression to advanced AMD.20
Again, the participants are divided into 4 groups. One group in the study will be
assigned to placebo, 1 to leutin/zeaxanthin, 1 to omega-3 LCPUFA, and 1 to the combination
of the 2. The AREDS II will include patients in AREDS Category 3 and 4 and the sample
size will be approximately 4000 patients. Approximately half of the participants
enrolled who choose to take the AREDS formulation will receive a new preparation
without beta-carotene. This will help determine the benefit beta-carotene made in
the formulation. In addition, the dose of zinc will be lowered by one half (40 mg)
in those who choose to take the AREDS formulation.
ALTERNATIVE THERAPY AND
Other unconventional nutrients have been
suggested to play a protective role in AMD. The best known is the extract anthocyanosides
of the vaccinium myrtillus (bilberry) plant, which is a potent antioxidant. Studies
have shown that bilberry has a strong affinity for the retinal pigment epithelial
cells and it may prevent macular degeneration in rat models.21
However, these results should be taken with caution since clinical trials have not
demonstrated its efficacy in humans as of yet.
Vitamins have been used to treat retinal diseases other than AMD.
Vitamin A with docosahexaenoic acid had been shown to reduce the progression of
retinitis pigmentosa over 2 years.22
Vitamin A has also been shown to help slow the progression of hereditary abetalipoproteinemia
and may be helpful as well in Sorsby fundus dystrophy.24
Refsum's disease may be treated with a diet low in phytanic acid.25
Finally, vitamin B6 along with a diet restricting arginine may be helpful in slowing
the progression of gyrate atrophy.26
Dietary supplementation with the AREDS formulation
of vitamins has clearly been shown in the AREDS I trial, a large, prospective, randomized,
placebo-controlled trial, to be of benefit in patients with intermediate and advanced
AMD (Categories 2-3). Ophthalmologists should educate themselves and their patients
as to which products and dosages are consistent with the AREDS recommendations.
Additionally, instructing patients to consume diets rich in fruits and vegetables,
particularly green leafy and yellow-orange vegetables, is reasonable.
Clinicians can use a simplified severity score from the AREDS
I study to better inform patients of their risk of AMD progression.27
Patients are evaluated for both macular drusen size and the presence or absence
of pigmentary abnormalities. Large drusen are those with a diameter >125
μm (the width of a retinal vein emerging from the optic disc). Patients receive
a point for each eye with at least 1 large druse, and a point for each eye with
pigment abnormalities. The maximum risk score therefore is 4. The risk of advanced
AMD within 5 years with risk factor scores of 0, 1, 2 ,3, and 4, respectively are:
0.5%, 3%, 12%, 25%, and 50% (Figure 3).
Understanding the beneficial effects of vitamin supplementation
has drastically changed how we approach patients with non-neovascular AMD. It allows
us an avenue to halt a relentless and destructive disease. Preventing disease progression
is far preferable to treating it once vision loss has occurred. We are anxiously
waiting to learn if lutein, zeaxanthin, and omega-3 fatty acids will prove to be
protective against the development of advanced AMD. The results from AREDS II will
ultimately determine whether these should be added to the currently accepted formulations.
As we continue to make headways in understanding the various etiologies of AMD,
we will be empowered to develop newer and more effective means of prevention, and
hopefully someday find a cure.
1. Gerster H. Review: antioxidant protection
of the ageing macula. Age Ageing. 1991;20:60-69.
2. Moriarty-Craige SE, Adkison J, Lynn M, et al. Antioxidant
supplements prevent oxidation of cysteine/cystine redox in patients with age-related
macular degeneration. Am J Ophthalmol. 2005;140;1020-1026.
Goldberg J. Flowerdew G, Smith E, et al. Factors associated with age-related macular
degeneration: an analysis of data from the first National Health and Nutrition Examination
Survey. Am J Epidemiol. 1988;128:700-710.
4. Delcourt C, Cristol JP, Tessier F, et al. Age-related macular
degeneration and anti-oxidant status in the POLA study. Arch Ophthalmol.
5. Age-Related Eye Disease Study Research Group. A randomized,
placebo-controlled clinical trial of high dose supplementation with vitamins C and
E, beta-carotene and zinc for age related macular degeneration and visual loss.
AREDS report no. 8. Arch Ophthalmol. 2001;119:1417-1436.
6. Newsome DA, Swartz M, Leone NC, et al. Oral zinc in macular
degeneration. Arch Ophthalmol. 1988;106:192-198.
7. Clemons TE, Kurinij N, Sperduto RD, AREDS Research Group.
Associations of mortality with ocular disorders and an intervention of high-dose
antioxidants and zinc in the Age-Related Eye Disease Study. AREDS Report no. 13.
Arch Ophthalmol. 2004;122:716-726.
8. Jampol L. Antioxidant, zinc, and age-related macular degeneration.
Arch Ophthalmol. 2001;119:1533-1534.
9. Flood V, Smith W, Wang JJ, et al. Dietary antioxidant intake
and incidence of early age-related maculopathy. Ophthalmology. 2002;109:2272-2278.
10. Kuzniarz M, Mitchell P, Flood VM, et al. Use of vitamin and
zinc supplements and age-related maculopathy: the Blue Mountain Eye Study. Ophthal
11. Taylor HR, Tikellis G, Robman LD, et al. Vitamin E supplementation
and macular degeneration. Br J Ophthalmol. 2002;325;1-6.
12. Bressler NM, Bressler SB, Congdon NG, et al. Potential public
health impact of Age-Related Eye Disease Study results: AREDS report no. 11.
Arch Ophthalmol. 2003;121:1621-1624.
13. Jampol L. AREDS-Two years later. Arch Ophthalmol. 2003; 1634-1636.
14. Arora S, Musadi M, Mukherji S, Yang YC. Eye nutrient products
for age-related macular degeneration: what do they contain? Eye. 2004;18:470-473.
15. Asplund K: Antioxidant vitamins in the prevention of cardiovascular
disease: a systematic review. J Intern Med. 2002;251:372-392.
16. Feskanich D, Singh V, Willett WC, et al. Vitamin A intake
and hip fractures among postmenopausal women. JAMA. 2002;287:47-54.
17. Snellen ELM, Verbeek ALM, van den Hoogen GWP, et al. Neovascular
age-related macular degeneration and its relationship to antioxidant intake. Acta
Ophthalmol Scand. 2002;80:368-371.
18. Mares-Perlman JA, Fisher AI, Klien R, et al. Lutein and zeaxanthin
in the diet and serum and their relation to age-related maculopathy in the third
national health and nutrition examination survey. Am J Epidemiol. 2001;153:424-432.
19. Seddon JM, Rosner B, Sperduto RD, et al. Dietary fat and risk
for advanced age-related macular degeneration. Arch Ophthalmol. 2001;119:
20. Chew EY and the Age-Related Eye Disease Study II Research
Group. American Academy of Ophthalmology, subspecialty day. 2005.
21. Fursova AZh, Gesarevich OG, Gonchar AM, et al. Dietary supplementation
with bilberry extract prevents macular degeneration and cataracts in senesce-accelerated
OXYS rats. Advances in Ge
22. Berson EL, Rosner B, Sandberg MA, et al. Further evaluation
of docosahexaenoic acid in patients with retinitis pigmentosa receiving vitamin
A treatment: subgroup analyses. Arch Ophthalmol. 2004;122:1306-1314.
23. Illingworth DR, Connor WE, Miller RG. Abetalipoproteinemia.
Report of two cases and review of therapy. Arch Neurol. 1980;37:659-662.
24. Jacobson SG, Cideciyan AV, Regunath G, et al. Night blindness
in Sorsby's fundus dystrophy reversed by vitamin A. Nat Genet. 1995;11:27-32.
25. Eldjarn L, Stokke O, Try K. Biochemical aspects of Refsum's
disease and principles for the dietary treatment. In Vinken PJ, Bruyn GW, eds. Handbook
of Clinical Neurology. Amsterdam: North-Holland. 1976;27:528.
26. Valle D, Walser M, Brusilow SW, Kaiser-Kupfer M. Gyrate atrophy
of the choroid and retina: amino acid metabolism and correction of hyperornithinemia
with an arginine-deficient diet. J Clin Invest. 1980;65:371-378.
27. Ferris FL, Davis MD, Clemons TE, et al. The Age-Related Eye
Disease Study (AREDS) Research Group. A simplified severity scale for age-related
macular degeneration: AREDS report no. 18. Arch Ophthalmol. 2005; 123:1570-1574.
Reddy, MD, is from the Department of Ophthalmology, New York University School of
Medicine. Howard F. Fine, MD, is from the Vitreous-Retina-Macula Consultants of
New York and the LuEsther T. Mertz Retina Research Center, Manhattan Eye, Ear, and
Throat Hospital. Neither author has financial interest in the information in this
article. Dr. Fine can be reached by e-mail at email@example.com.
Retinal Physician, Issue: May 2006